SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-122086
Filing Date
2023-04-27
Accepted
2023-04-27 16:02:00
Documents
16
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d488784d10ka.htm   iXBRL 10-K/A 314491
2 EX-31.3 d488784dex313.htm EX-31.3 3848
3 EX-31.4 d488784dex314.htm EX-31.4 3819
  Complete submission text file 0001193125-23-122086.txt   564545

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tsha-20221231.xsd EX-101.SCH 4589
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tsha-20221231_cal.xml EX-101.CAL 663
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tsha-20221231_def.xml EX-101.DEF 1668
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20221231_lab.xml EX-101.LAB 28712
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20221231_pre.xml EX-101.PRE 17817
10 EXTRACTED XBRL INSTANCE DOCUMENT d488784d10ka_htm.xml XML 7694
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39536 | Film No.: 23856638
SIC: 2836 Biological Products, (No Diagnostic Substances)